参考文献
1: Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew
AP, Coleman K, Crews CM. Hijacking the E3 Ubiquitin Ligase Cereblon to
Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. doi:
10.1016/j.chembiol.2015.05.009. PubMed PMID: 26051217; PubMed Central PMCID:
PMC4475452.
2: Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG,
Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS,
Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein
proteolysis-targeting chimera exerts superior lethal activity than bromodomain
inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML
cells. Leukemia. 2017 Jan 31. doi: 10.1038/leu.2016.393. [Epub ahead of print]
PubMed PMID: 28042144.
3: Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli
C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A,
Cippitelli M. Inhibition of bromodomain and extra-terminal (BET) proteins
increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated
cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J
Hematol Oncol. 2016 Dec 1;9(1):134. PubMed PMID: 27903272; PubMed Central PMCID:
PMC5131470.
